Lourdes Vázquez

Lourdes Vázquez

Auto-generated profile, based on publicly available information

Lourdes Vázquez

Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
ASA. Santaballa
A. Santaballa
CMC. Márquez-Vega
C. Márquez-Vega
ÁRÁ. Rodríguez-Lescure
Á. Rodríguez-Lescure
Ángeles RovirosaÁngeles Rovirosa
Ángeles Rovirosa
LVL. Vázquez
L. Vázquez
DMDolors Manau
Dolors Manau
Infertility is one of the main sequelae of cancer and its treatment in both children and adults of reproductive age. It is, therefore, essential that oncologists and haematologists provide adequate information about the risk of infertility and the possibilities for its preservation before starting treatment. Although many international clinical guidelines address this issue, this document is the first Spanish multidisciplinary guideline in paediatric and adult oncological patients. Experts from the Spanish Society of Medical Oncology, the Spanish Fertility Society, the Spanish Society of Haematology and Haemotherapy, the Spanish Society of Paediatric Haematology and Oncology and the Spanish Society of Radiation Oncology have collaborated to develop a multidisciplinary consensus.

5 January 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JSJose Luis Pinana Sanchez
Jose Luis Pinana Sanchez
LVLourdes Vazquez
Lourdes Vazquez
MMMarisa Calabuig Muñoz
Marisa Calabuig Muñoz
LLLucia López-Corral
Lucia López-Corral
GMGabriel Martin-Martin
Gabriel Martin-Martin
RODRIGO MARTINORODRIGO MARTINO
RODRIGO MARTINO
The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 to July 2022 by the Spanish Transplant and Cell Therapy group, was used to analyze the relationship of antibody response over time after full vaccination (at 3–6 weeks, 3, 6 and 12 months) (2 doses) and of booster doses with breakthrough SARS-CoV-2 infection in 1551 patients with hematological disorders. At a median follow-up of 388 days after complete immunization, 266 out of 1551 (17%) developed breakthrough SARS-CoV-2 infection at median of 86 days (range 7–391) after full vaccination. The cumulative incidence was 18% [95% confidence interval (C.I.), 16–20%]. Multivariate analysis identified higher incidence in chronic lymphocytic leukemia patients (29%) and with the use of corticosteroids (24.5%), whereas female sex (15.5%) and more than 1 year after last therapy (14%) were associated with a lower incidence (p < 0.05 for all comparisons). Median antibody titers at different time points were significantly lower in breakthrough cases than in non-cases. A serological titer cut-off of 250 BAU/mL was predictive of breakthrough infection and its severity. SARS-CoV-2 infection-related mortality was encouragingly low (1.9%) in our series. Our study describes the incidence of and risk factors for COVID-19 breakthrough infections during the initial vaccination and booster doses in the 2021 to mid-2022 period. The level of antibody titers at any time after 2-dose vaccination is strongly linked with protection against both breakthrough infection and severe disease, even with the Omicron SARS-CoV-2 variant.

28 February 2023 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
JSJose Luis Pinana Sanchez
Jose Luis Pinana Sanchez
RODRIGO MARTINORODRIGO MARTINO
RODRIGO MARTINO
LVLourdes Vazquez
Lourdes Vazquez
LLLucia López-Corral
Lucia López-Corral
APAriadna Pérez
Ariadna Pérez
S(Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)
Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)
The kinetics of SARS-CoV-2 reactive IgG antibodies after full vaccination and booster in allogeneic and autologous stem cell transplantation (allo-HSCT, ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) are of utmost importance for estimating risk of infection. A prospective multicenter registry-based cohort study, conducted from December 2020 to July 2022 was used to analyze antibody waning over time, booster effect and the relationship of antibody response and breakthrough infection in 572 recipients (429 allo-HSCT, 121 ASCT and 22 CAR-T cell therapy). A significant decline in antibody titers was observed at 3 and 6 months after full vaccination in recipients without pre-vaccine SARS-CoV-2 infection, whereas recipients infected prior to vaccination showed higher and stable antibody titers over time. In poor responders, a booster dose was able to increase antibody titers in 83% of allo-HSCT and 58% of ASCT recipients but not in CART-T cell recipients [0%] (p < 0.01). One-year cumulative incidence of breakthrough infection was 15%, similar among cell therapy procedures. Immunosuppressive drugs at the time of vaccination [hazard ratio (HR) 1.81, p = 0.0028] and reduced intensity conditioning (HR 0.49, p = 0.011) were identified as the only conditions associated with different risk of breakthrough infection in allo-HSCT recipients. Antibody titers were associated with breakthrough infection and disease severity. No death was observed among the 72 breakthrough infections. Antibody level decay after the first two vaccine doses was common except in recipients with pre-vaccination SARS-CoV-2 infection. Poorly responding allo-HSCT recipients showed a response advantage with the booster as compared to ASCT and, especially, the null response found in CAR-T cell recipients. Antibody titers were positively correlated with the risk of breakthrough SARS-CoV-2 infection which was mainly driven by the immunosuppression status.

1 September 2016 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
LVLourdes Vazquez
Lourdes Vazquez
Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. Antifungal prophylaxis in hematological patients is currently regarded as the gold standard in situations with a high risk of infection, such as acute leukemia, myelodysplastic syndromes, and autologous or allogeneic hematopoietic stem cell transplantation. Over the years, various scientific societies have established a series of recommendations for antifungal prophylaxis based on prospective studies performed with different drugs. However, the prescription of each agent must be personalized, adapting its administration to the characteristics of individual patients and taking into account possible interactions with concomitant medication.

1 December 2003 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
JPJose A Perez-Simon
Jose A Perez-Simon
IGI García-Escobar
I García-Escobar
JMJ Martinez
J Martinez
LVL Vazquez
L Vazquez
DCD Caballero
D Caballero
JMJ F San Miguel
J F San Miguel

16 January 2016 in Journal of Virological Methods
Verified
Journal Article
Closed access
MMMilagros Munoz-Chimeno
Milagros Munoz-Chimeno
JFJorge Forero
Jorge Forero
JEJ.M. Echevarría
J.M. Echevarría
JBJuan Luis Muñoz Bellido
Juan Luis Muñoz Bellido
LVL. Vázquez-López
L. Vázquez-López
AAAna Avellon
Ana Avellon